These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16469011)

  • 21. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
    Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
    Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
    Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
    [No Abstract]   [Full Text] [Related]  

  • 24. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transdermal Delivery of Luteinizing Hormone-releasing Hormone with Chitosan Microneedles: A Promising Tool for Androgen Deprivation Therapy.
    Chen MY; Chen YY; Tsai HT; Tzai TS; Chen MC; Tsai YS
    Anticancer Res; 2017 Dec; 37(12):6791-6797. PubMed ID: 29187457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW; Clarke HS; Hancock WC; Keane TE
    Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
    Meinhardt W; Horenblas S
    J Urol; 1999 Jul; 162(1):170-1. PubMed ID: 10379778
    [No Abstract]   [Full Text] [Related]  

  • 29. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
    Dearnaley DP; Norman AR; Shahidi M
    J Urol; 1999 Jul; 162(1):170. PubMed ID: 10379777
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).
    Langley RE; Cafferty FH; Alhasso AA; Rosen SD; Sundaram SK; Freeman SC; Pollock P; Jinks RC; Godsland IF; Kockelbergh R; Clarke NW; Kynaston HG; Parmar MK; Abel PD
    Lancet Oncol; 2013 Apr; 14(4):306-16. PubMed ID: 23465742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gonadotropin and steroid secretory patterns during chronic treatment with a luteinizing hormone-releasing hormone agonist analog in men.
    Evans RM; Doelle GC; Alexander AN; Uderman HD; Rabin D
    J Clin Endocrinol Metab; 1984 May; 58(5):862-7. PubMed ID: 6423661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrine response to a single injection of goserelin 3.6 mg or leuprolide 3.75 mg in men with prostate cancer.
    Tanaka N; Fujimoto K; Hirao Y; Shimizu K; Tsujimoto S; Samma S
    Arch Androl; 2007; 53(2):87-90. PubMed ID: 17453688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
    Mason M; Maldonado Pijoan X; Steidle C; Guerif S; Wiegel T; van der Meulen E; Bergqvist PB; Khoo V
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):190-6. PubMed ID: 23257248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In regard to Padula et al., normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. IJROBP 2002;52: 439-443.
    Dearnaley DP; Norman AR; Shahidi M
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):981; author reply 981. PubMed ID: 12377353
    [No Abstract]   [Full Text] [Related]  

  • 36. A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.
    Langley RE; Kynaston HG; Alhasso AA; Duong T; Paez EM; Jovic G; Scrase CD; Robertson A; Cafferty F; Welland A; Carpenter R; Honeyfield L; Abel RL; Stone M; Parmar MK; Abel PD
    Eur Urol; 2016 Jun; 69(6):1016-25. PubMed ID: 26707868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
    Petit JH; Gluck C; Kiger WS; Henry DL; Karasiewicz C; Talcott J; Berg S; Holupka E; Kaplan I
    Urol Oncol; 2008; 26(4):372-7. PubMed ID: 18367113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer.
    Padula GD; Zelefsky MJ; Venkatraman ES; Fuks Z; Lee HJ; Natale L; Leibel SA
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):439-43. PubMed ID: 11872290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis.
    McGivern U; Mitchell DM; McDowell C; O'Hare J; Corey G; O'Sullivan JM
    Clin Genitourin Cancer; 2012 Sep; 10(3):190-5. PubMed ID: 22677511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.
    Diamond TH; Winters J; Smith A; De Souza P; Kersley JH; Lynch WJ; Bryant C
    Cancer; 2001 Sep; 92(6):1444-50. PubMed ID: 11745221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.